Deprecated function: Creation of dynamic property Drupal\gmg_leaving_popup\Plugin\Block\AccessPopup::$routeMatch is deprecated in Drupal\gmg_leaving_popup\Plugin\Block\AccessPopup->__construct() (line 125 of modules/custom/gmg_leaving_popup/src/Plugin/Block/AccessPopup.php).
Patient Portrayal
ARE YOU LIVING WITH UNCONTROLLED gMG?
If you are experiencing uncontrolledgeneralized myasthenia gravis (gMG), you may have unpredictable and debilitating symptoms impacting your daily life—even with treatment.
gMG Never Rests is here to help you recognize the symptoms of uncontrolled gMG, communicate your experiences to your doctor, and connect with the gMG community.
When you sign up to receive updates from gMG Never Rests, UCB will make a donation to the Myasthenia Gravis Foundation of America (MGFA) to support their commitment to myasthenia gravis education, support, and research.
For US Healthcare Professionals Only
The contents of this website are intended for US healthcare professionals only.
By clicking “Continue to HCP site,” you are confirming that you are a US healthcare professional.
www.gMGNeverRests.com says
NOTICE: You are now leaving gMGNeverRests.com
This link is provided solely as a service to our website visitors. UCB, Inc. is not responsible for and does not endorse this third-party website.
Do you wish to continue?
CLOSE×
Thanks for your interest in learning more about treatments for generalized myasthenia gravis (gMG)
Unfortunately, this information is available only to those 18 years or older. Please continue to learn more about gMG by exploring this website.
Antibodies usually attach to harmful things like bacteria. However, in gMG your body starts producing abnormal antibodies that instead attach to normal proteins in the NMJ. Most people with gMG make AChR antibodies. These antibodies activate the complement system (part of the immune system). Complement disrupts the structure of the neuromuscular junction itself and is one of the main causes of damage in AChR+ gMG.
Occurring suddenly and lasting for a short time. An acute disease is one with symptoms that only last for a short period of time. People with myasthenia gravis often experience both acute and chronic symptoms.
Long-lasting, persistent, or constant. A chronic disease is one with symptoms that occur over a long period of time. People with myasthenia gravis often experience both chronic and acute symptoms.
A chronic autoimmune, neuromuscular disease that causes weakness in the skeletal muscles, which can worsen after periods of activity and improve after periods of rest. This weakness can affect moving, eating, and breathing.
MuSK antibodies are a type of antibody. Normally, antibodies attach to harmful things like bacteria. However, in gMG your body starts producing antibodies that instead attach to normal proteins in the NMJ. MuSK antibodies prevent the muscles from receiving messages properly from the nerves. When your muscles don't receive the signal, you experience muscle weakness.
An 8-category questionnaire that allows you and your doctor to measure the symptoms that most affect your daily living. Each category is graded on a scale of 0 (normal) to 3 (most severe). An MG-ADL score can be between 0 and 24, with a higher score meaning your symptoms are more severe.
As gMG affects each person differently, uncontrolled disease can also vary person to person. The most common signs and symptoms that may indicate uncontrolled disease include:
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL)—a tool your doctor may use to assess the extent of your symptoms)—greater than or equal to 6
Some but not all of the following: ongoing weakness, difficulty speaking, problems with chewing or swallowing, impaired vision or drooping eyelid, shortness of breath, or difficulty with activities such as brushing your teeth or combing your hair—which can impact your daily quality of life
Progression of symptoms requiring frequent treatment changes and/or increase in treatment dosing
It’s important to speak with your doctor if you are experiencing these signs and symptoms of gMG to understand if your disease may be uncontrolled.
Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60(6): 707-715.
Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141-149.
Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376-385.
Anil R, Kumar A, Alaparthi S, et al. Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry–The EXPLORE-MG registry. J Neurol Sci. 2020;414.
Kaminski HJ, Kusher LL. Myasthenia Gravis and Related Disorders. 3rd ed. Humana Press. 2018.
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22(7):1164-1169.
Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.
Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113-128.
Burden SJ, Yumoto N, Zhang W. The role os MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013;5(5):a009167.
Lindstrom J, Seybold M, Lennnon V, et al. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 1976;26:1054-1059.
Vincent A, Newson-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48:1246-1252.
Nagane Y, Muri H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2);e013278.
Twork S, Wiesmeth S, Flewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.
Simpson JA, Thomaides T. Treatment of myasthenia gravis: an audit. Q J Med.1987;64(244):693-704.